"From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. On the other hand, it did experience a revenue shortfall in the fourth quarter."
"Now, the share price is 13.2% higher than six months ago, including a 9.7% run in the past month, when Lilly announced multi-billion dollar investments in manufacturing plants in Virginia and Texas to help it avoid tariffs. It received key approvals from the FDA and the European Commission, and it hired a former FDA official to head its infectious disease unit."
"The question for investors is whether the latest move is more of the year's ongoing volatility or the stock has begun a sustained run higher. What will Lilly stock do in the next three to five years, and beyond? 24/7 Wall St. looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030."
Eli Lilly's stock rose over 635% from late 2020 to summer 2024, fueled by innovative medicines, regulatory approvals, pipeline advancement, and manufacturing investment. Last year delivered substantial financial growth but included a fourth-quarter revenue shortfall. The share price gained 13.2% over six months and 9.7% in the past month after multi-billion-dollar manufacturing investments in Virginia and Texas, FDA and European Commission approvals, and hiring a former FDA official to lead infectious disease. Revenue grew 60% since 2016 while net income rose 91%, and the valuation expanded from about 13× earnings in 2016 to roughly 72× today. Projected revenue and net income are being used to estimate 2025–2030 stock prices.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]